Ginkgo Bioworks announced its participation in the 27th American Society of Gene & Cell Therapy Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.
BOSTON, May 6, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics. These presentations demonstrate the power of Ginkgo’s platform to drive innovation in the discovery and development of genetic medicines.
Two cell therapy posters present results which extend the screening of pooled chimeric antigen receptor (CAR) libraries to in vivo mouse models and to NK cells. A third poster details how automated gene knock-in in induced pluripotent stem cells can enable high throughput screening workflows. The oral presentation will discuss the use of machine learning in the discovery of novel mRNA regulatory elements for increased stability and protein expression.
Over the past year, Ginkgo has significantly expanded its genetic medicines services (Gene Therapy, Cell Therapy, and RNA Therapeutics), which empower customers with Ginkgo’s capabilities for AI/ML-enabled massively parallel testing of genetic designs to leverage vast biological diversity to improve products.
In February, Ginkgo announced its acquisition of Patch Biosciences to further expand its suite of genetic medicine capabilities available to its customers. Ginkgo plans to incorporate Patch Bio’s machine learning models and downstream assays into its existing platform, making new capabilities in synthetic promoter and untranslated region (UTR) engineering available to partners. The addition of Patch Bio’s assets opens up additional commercial opportunities in gene therapy, cell therapy, and RNA therapeutics and has the potential to accelerate progress on current programs.
Shawdee Eshghi, Senior Director, Mammalian Engineering, Ginkgo Bioworks: “Our ASGCT presentations this year represent advances in large library screening in vivo and in vitro, the use of automation for high throughput genome engineering in iPSCs, and the application of machine learning to the design of improved gene therapies. We’re excited to demonstrate the value our services can bring to cell and gene therapy developers.”
Information on the poster presentations and oral presentation are listed below, and the full abstracts are available on the ASGCT meeting website.
Poster presentations:
- Pooled Screening for CAR Signaling Optimizes Function in NK Cells
Abstract number: 821
Session: Wednesday Poster Session
Presenter: Khloe Gordon Wei
Date and Time: Wednesday, May 8, 2024 12:00 PM ET - In Vivo Pooled Screening Platform for the Discovery of Optimized Chimeric Antigen Receptor (CAR) Design in T cells
Abstract number: 826
Session: Wednesday Poster Session
Presenter: Joshua Mace
Date and Time: Wednesday, May 8, 2024 12:00 PM ET - From Promoter to Transgene Efficiency: Insights from Promoter Screening in Induced Pluripotent Stem Cells
Abstract number: 1672
Session: Friday Poster Session
Presenter: Kiavash Kiaee
Date and Time: Friday, May 10, 2024 12:00 PM ET
Oral presentation:
- Machine-Designed Synthetic 3' UTRs Significantly Increase mRNA Stability
Abstract Number: 410
Session: Vector Product Engineering, Development, and Manufacturing (excluding AAV)
Presenter: Elise Flynn
Date and Time: Saturday, May 11, 2024 10:45 AM ET
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding Ginkgo’s capabilities in gene therapy, cell therapy, and RNA therapeutics, the benefits of Ginkgo’s acquisition of Patch Bio, and the potential success of Ginkgo’s cell programming platform. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 29, 2024 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-presentations-at-the-upcoming-american-society-of-gene--cell-therapy-asgct-annual-meeting-302136381.html
SOURCE Ginkgo Bioworks
Company Codes: NYSE:DNA
